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Abstract
Background: Malignant melanoma is the deadliest form of skin cancer and is refractory to conventional chemotherapy and
radiotherapy. Therefore alternative approaches to treat this disease, such as immunotherapy, are needed. Melanoma
vaccine design has mainly focused on targeting CD8
+ T cells. Activation of effector CD8
+ T cells has been achieved in
patients, but provided limited clinical benefit, due to immune-escape mechanisms established by advanced tumors. We
have previously shown that alphavirus-based virus-like replicon particles (VRP) simultaneously activate strong cellular and
humoral immunity against the weakly immunogenic melanoma differentiation antigen (MDA) tyrosinase. Here we further
investigate the antitumor effect and the immune mechanisms of VRP encoding different MDAs.
Methodology/Principal Findings: VRP encoding different MDAs were screened for their ability to prevent the growth of the
B16 mouse transplantable melanoma. The immunologic mechanisms of efficacy were investigated for the most effective
vaccine identified, focusing on CD8
+ T cells and humoral responses. To this end, ex vivo immune assays and transgenic mice
lacking specific immune effector functions were used. The studies identified a potent therapeutic VRP vaccine, encoding
tyrosinase related protein 2 (TRP-2), which provided a durable anti-tumor effect. The efficacy of VRP-TRP2 relies on a novel
immune mechanism of action requiring the activation of both IgG and CD8
+ T cell effector responses, and depends on
signaling through activating Fcc receptors.
Conclusions/Significance: This study identifies a VRP-based vaccine able to elicit humoral immunity against TRP-2, which
plays a role in melanoma immunotherapy and synergizes with tumor-specific CD8
+ T cell responses. These findings will aid
in the rational design of future immunotherapy clinical trials.
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Introduction
Melanoma differentiation antigens (MDAs) include tyrosinase,
pMEL17/gp100, gp75/tyrosinase related protein (TRP)-1,
MART-1/melan-A and dopachrome tautomerase/TRP-2 and
represent ideal target antigens for melanoma immunotherapy, due
to preferential expression in melanocytes and melanoma cells [1].
Although eliciting immune responses against MDAs has been
challenging because self tolerance hampers complete activation of
adaptive immunity [2], recent progress with melanoma vaccines
has provided proof of principle that T cell immunity to MDAs can
be actively induced in advanced melanoma patients. However,
established tumors develop an array of immune-escape mecha-
nisms that inhibit effector T cells and/or prevent full T cell
activation [3,4], limiting the clinical benefit. The notion the tumor
immune-escape mechanisms are heterogeneous and multifaceted
has challenged the idea of a central and unique role for CD8
+ T
cells in tumor immunotherapy. An emerging concept is that
targeting multiple arms of immunity may be important to
counteract tumor immune-escape at different levels. Indeed, it
has recently been shown that targeting regulatory T cells or
effector CD4
+ T cells is therapeutic [5,6,7] suggesting that
combined activation/deactivation of different T cell populations
might be beneficial.
Activation of humoral responses may represent further
improvement of current T cell-based melanoma immunotherapy
strategies. Monoclonal antibodies targeting tumor surface antigens
such as HER2/neu, CD20, EGF receptor and CD52, for
example, are effective for the treatment of other malignancies,
through immune cell-dependent and independent mechanisms
[8]. The development of melanoma-specific humoral immunity to
numerous surface and intracellular melanoma antigens, including
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recent observation that antigen-specific B cell immune responses
correlate with durable objective clinical responses and stable
disease in metastatic melanoma patients undergoing immunother-
apy [12], suggests that IgGs may play a role in immune
surveillance. A monoclonal antibody recognizing mouse gp75/
TRP-1 has been generated and has shown activity in mice when
infused either as single agent or in combination with vaccines
eliciting CD8
+ T cell responses [13,14]. However, inducing anti-
tumor humoral immunity against MDAs through active vaccina-
tion has been a more elusive goal and the anti-tumor potential of
humoral immunity has not been thoroughly appreciated in
melanoma [15,16].
Recombinant viral vectors have been investigated as a means of
vaccination because they can carry full-length antigen-encoding
genes, have the capacity to produce these antigens in large
quantities, and may contain helper epitopes. Alphaviruses are
positive-stranded RNA viruses. An attenuated variant of one
member of this family, the Venezuelan equine encephalitis virus
(VEE), has been developed as a propagation-defective virus-like
replicon particle (VRP). VEE-based VRP have been shown to
induce high titers of antibodies and robust antigen-specific T cell
responses against encoded antigens in mice [17,18,19,20,21,22,23]
and more recently in healthy human subjects [24]. At the same
time, neutralizing anti-vector immunity does not appear to
preclude benefit from repetitive booster vaccinations in mice
[25,26,27,28,29] as opposed to other viral vectors. VRP generate
double-stranded RNA that stimulates innate immune responses
through RNA binding receptors [22,30,31], potent inducers of
innate antiviral responses, including type I IFNs [32].
An alphavirus-based DNA vaccine encoding gp75/TRP-1
induces immunity to both mouse and human gp75/TRP-1 [21].
Similarly, we have shown that VRP containing either syngeneic
(mouse) or human tyrosinase are immunogenic as opposed to
plasmid DNA vaccination, which requires the use of xenogeneic
(human) tyrosinase to overcome immunologic ignorance and/or
tolerance [33]. Interestingly, VRP can elicit both antibodies and
CD8
+ T cell responses against tyrosinase.
Given the very attractive ability of VRPs to induce humoral and
T cell responses against tyrosinase, we sought to further investigate
the potentials of VRP encoding different MDAs as vaccines for
melanoma. We found that VRP-encoded TRP-2 (VRP-TRP2) is
the most effective target antigen among those tested. The VRP-
TRP2 vaccine has a surprisingly potent therapeutic anti-tumor
effect as a single agent on B16 tumors. We also found that the
efficacy of VRP-TRP2 relies on its ability to elicit TRP-2 specific
antibodies. Here we report for the first time that TRP-2 specific
antibodies, induced by active immunization, synergistically co-
operate to tumor protection together with CD8
+ T cells.
Results
Screening the best MDA encoded by VRPs in a
prophylactic setting
To investigate the efficacy of VRPs encoding MDAs as an
immunotherapeutic approach for melanoma, we compared VRP
encoding the mouse MDAs tyrosinase (tyr), gp100 or TRP-2. VRP
were administered in a prophylactic setting, prior to intradermal
(i.d.) challenge with the aggressive and poorly immunogenic B16
melanoma line. Shown in Figure 1A, mice vaccinated with VRP-
gp100 and VRP-tyr developed tumor within 18 days, similar to
untreated mice or control mice injected with VRP expressing
green fluorescent protein (GFP, VRP-GFP). However, the VRP-
TRP2 vaccine provided a significant delay in tumor occurrence
and long-term tumor protection (Figure 1A). Vaccination with
VRP-TRP2 was more effective than combination of VRP-gp100
and VRP-tyr, and the efficacy of the combination of all three VRP
expressing the different melanoma antigens was not significantly
better than VRP-TRP2 alone (Figure 1B). Depigmentation was
observed in only in 5–10% of immunized animals. These results
suggested that TRP2 is the most relevant antigen to target with
VRP in a prophylactic setting; therefore, we focused on this
vaccine and further characterized its preclinical potential by
testing it in more stringent therapeutic experimental conditions.
VRP-TRP2 in a therapeutic setting
The anti-tumor effect of VRP-TRP2 treatment was evaluated in
a more clinicallyrelevant therapeuticsetting.Tothisend, micewere
injected with B16 to establish skin tumors prior to receiving
vaccination with VRP-TRP2. VRP-TRP2 induced time-dependent
tumorprotectionwhen vaccinationwasstartedaslateas5daysafter
tumor inoculation (Figure 2A). Similar therapeutic potency was
observed in a different challenge model, where B16 is injected
intravenously (i.v.) and develops as tumor nodules in the lung. Mice
treated with VRP-TRP2 developed fewer lung tumors when
compared to control mice (Figure 2B and 2C). These data indicated
that TRP-2-specific immune responses developed rapidly in the
VRP-TRP2 vaccinated animals and were effective in regressing
tumors in different anatomic locations. Although prophylaxis
against B16 implantation can be achieved by many types of
Figure 1. VRP-TRP2 has a potent anti-tumor effect in a prophylactic setting. Kaplan-Meier tumor-free survival curves are shown for 10/15
mice per group. Mice received i.d. injections of VRP expressing TRP-2, gp100, tyrosinase (A) or combination of those antigens (B) prior to challenge
with B16 melanoma (prophylactic setting). As a negative control, groups of mice were injected with VRP-GFP or left untreated (NAI ¨VE). *** P,0.0001,
** P,0.001, * P,0.01.
doi:10.1371/journal.pone.0012670.g001
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only be accomplished by the combination of vaccination with other
treatment modalities [34]. In the cutaneous therapeutic setting,
tumors develop very rapidly and reach a size of 1 cm
2 at day 25–35
in close to 100% of untreated mice. The surprising therapeutic
effect of the VRP-TRP2 vaccine as monotherapy in un-manipu-
lated B16 tumor with these stringent conditions, prompted further
investigation of the mechanism(s) underlying tumor immunity.
VRP-TRP2 induces TRP-2 specific CD8+ T cell responses
and accumulation of CD8+ T cells in the tumor
It has been shown that the anti-tumor effect of TRP-2 specific
DNA vaccines is CD8
+ T cell dependent [35,36]. We therefore
first considered the possibility that the anti-tumor activity of VRP-
TRP2 may depend on the activation of TRP-2 reactive CD8
+ T
cells. To investigate this, we performed ex vivo and in vivo analyses
of CD8
+ T cell responses. Measurement of IFNc production by
ELISPOT assays and intracellular flow cytometry staining showed
that immunization with VRP-TRP2 induced CD8
+ T cells that
were responsive to the TRP-2181–188 peptide (Figure 3A and
Figure S1A). VRP-TRP2 induced CD8
+ T cells also recognized
B16 cells as a target in vitro (Figure 3A). VRP-TRP2 induced a
stronger CD8
+ T cell response against the TRP-2181 immunodo-
minant epitope when compared to the reactivity elicited by VRP-
gp100 and VRP-tyr against the gp10025 and tyr360 immunodo-
minant epitopes, respectively (Figure S1B).
We measured the quality and quantity of the immune infiltrate
in B16 tumors implanted after vaccination. The percentage of
tumor infiltrating CD45
+ cells significantly increased when mice
were immunized with VRP-TRP2 as compared to VRP-GFP or
naı ¨ve mice (Figure S2). The quality of the CD45
+ immune tumor
infiltrate also selectively changed with an increase in the
percentage of CD3
+CD8
+ T cells recruited at the tumor site,
indicating that B16 reactive CD8
+ T cells were trafficking to tumor
Figure 2. VRP-TRP2 has a potent anti-tumor effect in a therapeutic setting. (A) Kaplan-Meier tumor-free survival curves are shown for 10/15
mice per group. Mice received i.d. injections of VRP expressing the indicated MDAs either 1or 3 days after challenge with B16 melanoma (therapeutic
setting). As a negative control, groups of mice were injected with VRP-GFP or left untreated (NAI ¨VE). (B) Representative photograph and (C) weight of
lungs resected 24 days after tumor inoculation from mice treated with VRP-GFP or VRP-TRP2 (lung therapeutic model). Each dot represents an
individual mouse. *** P,0.0001, ** P,0.001.
doi:10.1371/journal.pone.0012670.g002
Figure 3. VRP-TRP2 elicits a tumor-specific CD8
+ T cell responses. (A) ELISPOT analysis of IFNc secreting CD8
+ T cells purified from spleens of
mice immunized with control VRP-GFP or VRP-TRP2 and re-stimulated with TRP-2181 peptide, B16 cells or an irrelevant peptide (IRR). Mean value and
standard error represents 3/5 spleens analyzed individually per group. (B–D) Flow cytometric analysis of immune cell lineages infiltrating B16-
matrigel plugs. (B) Representative photograph of B16-matrigel plugs of mice vaccinated with control VRP-GFP or VRP-TRP2 and (C) representative
dot plot. (D) Immune infiltrate analysis expressed as a percentage of total CD45
+ leukocytes. Mean percentage and standard error represent 4/5
tumors analyzed individually per group.
doi:10.1371/journal.pone.0012670.g003
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NK cells was also observed in VRP-TRP2 vaccinated mice,
whereas the percentage of T cells, B cells, NKT cells and CD11c
+
dendritic cells remained unchanged (Figure 3D).
CD8
+ T cells are important but are not the only cell type
responsible for tumor protection
In order to determine which components of the immune system
contribute to the anti-tumor effect induced by the vaccine, we
depleted effector T cells (both CD4
+ and CD8
+), NK and NKT
cells with depleting antibodies in vivo, after vaccination. Despite
the consistent recruitment of CD8
+ T cells to tumor (Figure 3D),
depletion of effector T cells after vaccination only partially
decreased tumor-free survival upon B16 challenge (Figure 4A).
Depletion of NK and NKT cells did not affect the anti-tumor
effect, ruling out a possible contribution of these cells in VRP-
TRP2 mediated anti-tumor immunity (Figure 4A). To further
investigate the role of T cells in tumor protection we immunized
MHC I deficient mice, which lack CD8
+ T cells. VRP-TRP2
immunized MHC I deficient mice showed a lower degree of
protection than that observed in control wild-type (WT) mice, but
had a significantly better outcome as compared to similar mice
immunized with control VRP-GFP (Figure 4B). This indicated
that the anti-tumor effect of VRP-TRP2 does not only rely on
effector CD8
+ T lymphocytes. To investigate the role of other
immune components we tested the VRP-TRP2 vaccine in MHC
II deficient mice, which lack CD4
+ T cells and did not mount
TRP2-specific CD8
+ T cell responses (Figure S3). The anti-tumor
effect of VRP-TRP2 was completely abrogated in MHC II
deficient mice (Figure 4B). Interestingly, MHC I deficient mice
showed a better degree of protection than MHC II deficient mice
(Figure 4B), implying a CD4
+ T cell-dependent CD8
+ T cell-
independent mechanism of tumor protection.
TRP-2 expressing VRPs induce TRP2-specific IgGs
Since the simultaneous depletion of CD4
+ and CD8
+ effector T
cells after vaccination did not completely abrogate tumor
protection (Figure 4A), we hypothesized that CD4
+ T cells may
contribute to the antitumor effect of VRP-TRP2 through the
activation of B cell responses and therefore investigated a role for
humoral immunity.
Mice immunized with VRP-TRP2 developed TRP-2 specific
serum IgG that recognized recombinant TRP-2 protein by ELISA
(Figure 5A, left panel). This was not observed in mice immunized
with the control VRP-GFP vaccine (Figure 5A, right panel). The
titer of TRP-2 specific IgG increased over time following repetitive
vaccinations (Figure 5B). Sera from VRP-TRP2 immunized mice
also recognized endogenous murine TRP-2 expressed by B16 cells,
as assessed by Western blot analysis on tumor protein extracts
(Figure 5C). By using a library of overlapping peptides (Figure S4)
we found that the serum from VRP-TRP2 immunized mice was
preferentially reactive to a region spanning amino acids 51–101 of
mouse TRP-2 (Figure 5D). The induction of TRP-2-specific IgG
was entirely MHC II dependent but did not require MHC I
(Figure 5E), suggesting that TRP-2 specific IgG may indeed
account for the residual anti-tumor activity of VRP-TRP2
observed in MHC I deficient mice (Figure 4B).
The humoral response induced by VRP-TRP2 is important
for tumor protection and requires Fc receptors (FcR)
To evaluate whether the TRP-2 antibody response plays a role
in tumor protection, sera from mice immunized with VRP were
transferred to recipient mice that were challenged on the same day
with B16. VRP-TRP2 immune sera delayed tumor growth when
compared with sera from mice immunized with VRP expressing
other antigens (Figure 6A). To further investigate the IgG-
dependent mechanism underlying the anti-tumor effect, mice
deficient in the common c chain (FcRc
2/2) were vaccinated with
VRP-TRP2. FcRc
2/2 mice were less protected compared with
FcRc
+/2 littermate controls (Figure 6B). These results indicated
that the antibody-dependent anti-tumor effect involves signaling
through activating Fc receptors. FcRc
2/2 and FcRc
+/2 controls
induced similar levels of TRP-2 specific IgG (Figure S5); therefore,
the reduced tumor protection is likely due to the lack of IgG
effector function and not to inherent inability of FcRc
2/2 mice to
activate humoral responses. By contrast, C3
2/2 animals showed a
similar level of tumor protection as WT controls (Figure 6C),
ruling out a major role for complement in the anti-tumor effect.
Discussion
Heterogeneity of immune escape mechanisms leads to the
suggestion that targeting multiple arms of immunity could be a key
Figure 4. VRP-TRP2 anti-tumor effect is only partially CD8
+ T
cell dependent. (A) Kaplan-Meier tumor-free survival curves of 10
mice per group vaccinated with either control VRP-GFP or VRP-TRP2
and treated with depleting antibodies for NK/NKT or T cells after the last
vaccination. (B) Kaplan-Meier tumor-free survival curves of 15 WT, MHC
I and MHC II deficient mice per group vaccinated with either control
VRP-GFP or VRP-TRP2. *** P,0.0001, ** P,0.001.
doi:10.1371/journal.pone.0012670.g004
VRP TRP-2 Vaccine for Melanoma
PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12670to the development of more potent immunotherapies. Most pre-
clinical and clinical studies of melanoma vaccines have focused on
eliciting tumor-specific CD8
+ T cells, which can be very effective
in preventing tumor occurrence but may not be sufficient to
control tumor growth when the tumor is already established. Here
we have evaluated the efficacy of non replicative alphavirus-based
as vaccines for melanoma and we have shown that (1) the choice of
the target antigen determines the therapeutic outcome and (2) the
mobilization of humoral immunity is an important step in
optimizing the efficacy of TRP-2 specific melanoma vaccines.
We have first found that a VRP vaccine targeting TRP-2 is
surprisingly effective in controlling tumor growth as opposed to
vaccines based on the same viral delivery vector targeting the other
melanosomal antigens, gp100 and tyrosinase. Therefore, although
TRP-2, gp100 and tyrosinase are all MDAs expressed in the
melanosome, their relative immunogenicity and therapeutic
potential is different, at least when delivered via VRPs. In addition
to its intrinsic immunogenicity, the relevance of TRP-2 as a target
antigen may also relate to the TRP-2 protein’s localization and
function. TRP-2 is a transmembrane melanosomal glycoprotein
required for melanin biosynthesis and its expression is restricted
mainly to the melanocyte, melanoblasts and retinal pigmented
epithelium [1,37,38,39]. Although TRP-2 expression in normal
melanocytes is targeted to the melanosomes, the polypeptide
matures in the endoplasmic reticulum and a small proportion of
TRP-2 can be found in the plasma membrane [40,41], therefore
providing a target for antibodies.
TRP-2 has DOPAchrome tautomerase enzymatic activity and
catalyzes the conversion of DOPAchrome to 5,6,dihydroxyndole-
2-carboxylic acid, a precursor of brown melanins. It has been
proposed that TRP-2 may maintain cell viability by controlling the
intracellular concentration of 5,6-dihydroxyndole, a toxic inter-
mediate of melanin biosynthesis [42]. Mice with mutations in the
TRP-2 gene have a lighter color coat (Slaty) as compared to wild
type C57BL/6 mice, due to decreased catalytic function [43]. In
addition, TRP-2 is expressed in migratory melanoblasts early after
they emerge from the neural crest, whereas other MDAs, such as
tyrosinase and TRP-1 are expressed later in development [37].
Early expression of TRP-2 in melanogenesis may also contribute
to its relevance as a tumor immunotherapy target given the
heterogeneity in differentiation state of individual melanomas [10].
It has been previously reported that TRP-2 specific CD8
+ T cell
responses can be induced in humans and in mice [35,44]. Here we
demonstrate for the first time that TRP-2 specific humoral
immunity induced by VRP vaccination is another important
component of active immunization to achieve long term tumor
protection. Indeed, although either tumor specific CD8
+ T cells or
IgG alone are sufficient to provide a significant short term tumor
protection, both are required for long term protective immunity.
This suggests that activating both arms of immunity is an
important requirement to subvert immune-escape mechanisms
against established and rapidly growing tumors such as the poorly
immunogenic B16 melanoma. The ability of the alphavirus-based
VRP vaccine to achieve this dual immune effect may rely on the
Figure 5. VRP-TRP2 elicits a TRP2-specific antibody response. (A,B) Measurement of TRP-2-specific serum IgG by ELISA. (A) Serial dilutions of
sera from mice immunized with VRP-TRP2 (left panel) or VRP-GFP (right panel). Each line represents an individual mouse. (B) 1:100 dilution of sera
from mice immunized with VRP-TRP2 one week after the first (week 1), the second (week 3) or the third vaccination (week 5). Each line represents an
individual mouse. (C) Western blot analysis of sera from VRP-TRP2 or VRP-GFP immunized mice and a commercial TRP-2 specific antibody (anti-TRP2)
against B16 or Lewis Lung (LL) cell lysates. (D) Measurement of TRP-2-peptide specific serum IgG by ELISA. 1:100 dilution of sera from mice
immunized with VRP-TRP2 were tested against the indicated TRP-2 peptide pools. (E) 1:100 dilution of sera drawn from WT, MHC I or MHC II deficient
mice immunized with VRP-TRP2 or VRP-GFP were analyzed. Each dot represents sera from individual mice. *** P,0.0001.
doi:10.1371/journal.pone.0012670.g005
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innate immune cells. In vitro experiments have shown that the
RNA component of the VRP delivery system contributes to its
immunogenicity by triggering inflammatory signals through RNA
binding receptors such as RIG-I and MDA-5 [21,22,30,31]. The
activation of cytoplasmic RNA sensing pathways in specific
antigen presenting cell subsets in vivo may therefore be an
important requirement for an adjuvant to overcome tolerance to
self antigens and prime multifaceted immune responses.
We have shown that the anti-tumor activity of VRP-TRP2 is in
part mediated by signaling through activating Fc receptors and not
through C3a-receptor. This suggests that antibody-dependent cell
mediated cytotoxicity (ADCC) rather than complement mediated
lysis, is important for the in vivo anti-cancer effect. It is emerging
that Fc receptors play an important role in modulating in vivo
anti-tumor toxicity of therapeutic monoclonal antibodies [45].
TRP-2 directed Fc-dependent ADCC may require direct killing of
IgG coated targets by Mac-1 expressing neutrophils or macro-
phages [46,47]. Alternatively, FcR-mediated uptake of dying
tumors may result in cross presentation and induction of a
broader-spectrum immune protection. The two possibilities are
not mutually exclusive and will require further investigation.
Immunization against MDAs can cause skin hypopigmentation,
as consequence of autoimmune reactions to normal melanocytes
[9]. Tumor protection induced by prophylactic immunization with
mouse TRP-2 can correlate to different degrees of hypopigmen-
tation depending on the vaccination regimen [36,48]. TRP-2 may
also have antigenic potential in humans, as a significant anti-TRP2
antibody titer was observed in patients with vitiligo [49]. To our
surprise, we found that VRP-TRP2 induced very little hypopig-
mentation in mice, confined to the site of tumor injection. This
feature is attractive, in that the potency of this vaccine does not
seem to correlate with severe autoimmune side effects in mice.
Our preclinical work has identified a new potent therapeutic
vaccine that provides long-term protection against melanoma
through concomitant activation of antibodies and CD8
+ T cells
targeting the self antigen TRP-2. Our studies demonstrate for the
first time that targeting TRP-2 with both humoral and cellular
immunity is a valuable approach to enhance the efficacy of
melanoma vaccine on established tumors. These findings will be
instrumental in designing future immunotherapeutic approaches
for melanoma and support further investigation on the efficacy of
VRP-TRP2 in melanoma patients.
Materials and Methods
Mice and cell lines
All mouse procedures were performed in accordance with
institutional protocol guidelines at Memorial Sloan-Kettering
Cancer Center (MSKCC). C57BL/6J (8–10-wk-old females) and
C3 deficient mice (strain B6.129S4-C3tm1crr/J) were obtained
from the Jackson Laboratory. MHC class I deficient (strain
B2MN12), MHC class II deficient (strain ABBN12) and WT
control mice (strain B6NTac) were purchased from Taconic
Farms. Mice deficient in the FcR common c chain, provided by J.
Ravetch (Rockefeller University, New York, New York) were
backcrossed onto WT C57BL/6 and bred at MSKCC. Mice were
maintained according to NIH Animal Care guidelines, under a
protocol 96-04-017 approved by the MSKCC Institutional Animal
Care Committee. The B16-F10 mouse melanoma line was
originally obtained from I. Fidler (M.D. Anderson Cancer Center,
Houston, TX).
VRP preparation
Mouse tyrosinase, gp100 and TRP-2 cDNAs were cloned into
the pERK replicon vector and VRP were generated as previously
described [50].
VRP immunization and tumor challenge
C57BL/6 mice were vaccinated three times at two week
intervals with 10
6 VRP diluted in PBS by subcutaneous (s.c.)
Figure 6. VRP-TRP2 humoral anti-tumor effect is mediated by
Fc Receptors. Kaplan-Meier tumor-free survival curves of (A) 7–9
NAI ¨VE recipient mice per group, transferred with sera from donor mice
vaccinated with the indicated VRP; (B) Eight to 14 FccR 2/2 or +/2
littermate control mice vaccinated with VRP-TRP2 or VRP-GFP; (C)
Twelve C3 2/2 or +/+ control mice vaccinated with VRP-TRP2 or VRP-
GFP. *** P,0.0001, ** P,0.001, * P,0.01.
doi:10.1371/journal.pone.0012670.g006
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tumor protection experiments, mice were challenged with 7.5610
4
B16F10 cells intradermally (i.d.) two weeks after the last
vaccination with VRP. For T cell depletion experiments, CD4+
cells, CD8+ cells and NK/NKT cells were depleted by
intraperitoneal injection of 200 mg of GK1.5, 2.43 and PK136
antibodies (Monoclonal Antibody Core Facilty, MSKCC) respec-
tively, at day 211, 24, +4, +11 relative to tumor inoculation. In
therapeutic tumor protection experiments, mice were first
challenged with 7.5610
4 B16F10 cells either i.d. (cutaneous
therapeutic model) or i.v. (lung therapeutic model), and then
vaccinated weekly for three times. Animals were monitored every
2 to 3 days for 80 days. For the Kaplan-Meier tumor free survival
curves, mice were considered tumor free until tumors were visible
or palpable. P values were calculated with log-rank (Mantel-Cox)
test.
T cell assays
Spleens were harvested 5 to 7 days after the last VRP
immunization and CD8
+ T cells were positively selected for
standard ELISPOT assays as previously described [14]. Flow
cytometry based intracellular staining assays were performed on
CD8
+ T cells purified from the spleen and then incubated overnight
with monensin prior to staining with the fixation and permeabiliza-
tion kit (eBioscience) using anti-CD8-PE–Texas red, anti-CD3-
FITC, anti-IFNc-APC (BD) and LIVE/DEAD Fixable Aqua
Dead Cell Stain kit (ViD). TRP2181–189, gp10025–33, tyr360–368
and the overlapping peptide library were synthesized by Genemed
Synthesis at .80% purity.
Analysis of the tumor infiltrate
Seven days after B16-matrigel s.c. injection (1610
5 B16-F10
cells in 0.2 ml of Matrigel Matrix Growth Factor Reduced; BD),
the matrigel plug was resected, incubated for 1 hour at 37uC with
1 mg/ml Collagenase D (Sigma) and dissociated to obtain a single-
cell suspension. Cells were stained with anti-CD45.2 PercpCy5.5,
anti-CD3-FITC, anti-NK1.1-APC, anti-CD8-PE–Texas red, anti-
CD4- Alexa Fluor 700 (BD) and DAPI.
ELISA and Western blot
Seven days after the last VRP immunization, mice were bled
from the lateral tail vein or via cardiac puncture. Sera were
analyzed by ELISA using plates coated with a purified
recombinant TRP2 protein in PBS and goat anti mouse IgG-AP
(Southern Biotech), as a detection antibody. The AttoPhos AP
substrate was purchased from Promega (#S1013). Plates were
read with Perceptive Biosystems, Cytoflour Series 4000 at
Excitation 450/50 and Emission 580/50 with gain of 25. Western
blotting was performed using sera pooled from immunized mice
and diluted 1:100 in PBS+0.1% Tween20 and incubated
overnight at 4uC.
Passive transfer of immune sera
Sera were collected from mice 7 days after the last VRP
immunization. 50 ul of sera were injected i.v. in recipient mice at
day 0, 3 and 6. Recipient mice were challenged with 7.5610
4 B16
cells i.d. at day 0 and tumor occurrence was monitored as
described above.
Supporting Information
Figure S1 CD8+ T cell antigen specific IFNgamma production.
(A) Flow cytometric analysis of IFNgamma+CD8+ T lymphocytes
purified from spleens of mice immunized with control VRP-GFP
or VRP-TRP2, and re-stimulated with TRP-2181 peptide or an
irrelevant peptide (IRR). (B) ELISPOT analysis of IFNgamma
secreting CD8+ T cells purified from spleens of mice immunized
with control VRP-GFP, VRP-TRP2, VRP-gp100 or VRP-tyr and
re-stimulated with TRP-2181, gp10025, tyr360 or an irrelevant
peptide (IRR). Data shown represents the average of 3 individual
mice.
Found at: doi:10.1371/journal.pone.0012670.s001 (5.17 MB TIF)
Figure S2 Analysis of CD45+ tumor immune infiltrate. Flow
cytometric analysis of the B16-matrigel immune infiltrate. (A)
Representative dot plots and gating strategy. (B) The percentage of
CD45+ cells among total live (DAPI-) cells is reported. Each dot
represents an individual tumor analyzed, mean and standard
errors are reported. ** P,0.001.
Found at: doi:10.1371/journal.pone.0012670.s002 (5.15 MB TIF)
Figure S3 Analysis of TRP2-specific CD8+ T cell in MHC II
KO mice. ELISPOT analysis of IFNgamma secreting CD8+ T
cells purified from spleens of mice immunized with control VRP-
GFP or VRP-TRP2 and re-stimulated with TRP-2181 or an
irrelevant peptide (IRR). Mean value and standard error
represents 3 spleens analyzed individually per group. ** P,0.001.
Found at: doi:10.1371/journal.pone.0012670.s003 (4.63 MB TIF)
Figure S4 Overlapping TRP2 peptide library. A library of 102
overlapping peptides spanning the whole sequence of the TRP-2
protein was divided in 10 pools, each containing the indicated
peptides.
Found at: doi:10.1371/journal.pone.0012670.s004 (6.21 MB TIF)
Figure S5 Analysis of TRP2-specific IgG responses in Fcgam-
maR KO mice. Measurement of TRP-2 specific serum IgG by
ELISA. 1:100 dilution of sera drawn from FcgammaR2/2 or
FcgammaR+/2 mice immunized with VRP-TRP2 or VRP-GFP
were analyzed. Each dot represents sera from individual mice.
** P,0.01.
Found at: doi:10.1371/journal.pone.0012670.s005 (4.44 MB TIF)
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